USPTO serial 90266118
TEVA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 19, 2023
- Examiner
- HOWELL, MATTHEW P
- Law office
- TMO LAW OFFICE 123
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with TEVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Teva Pharmaceutical Industries Ltd.
Jerusalem, IL
Other trademarks owned by Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Tel Aviv, IL
Other trademarks owned by Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Tel Aviv, IL
Other trademarks owned by Teva Pharmaceutical Industries Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Laurence Rickles
400 INTERPACE PARKWAYPARSIPPANY, NJ 07054UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system | ACTIVE | Nov 1, 2013 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Teva Pharmaceutical Industries Ltd.
- Other trademarks owned by Teva Pharmaceutical Industries Ltd.
- Other trademarks owned by Teva Pharmaceutical Industries Ltd.
- Other trademarks in Class 005
- Similar marks named TEVA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 19, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 19, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 14, 2023 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 13, 2023 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 13, 2023 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Nov 8, 2023 | IUAF | USE AMENDMENT FILED | — |
| Nov 8, 2023 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| May 2, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 28, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 28, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 28, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 4, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 2, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 2, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 2, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 17, 2022 | EX3M | SOU EXTENSION 3 DENIAL LETTER MAILED | — |
| May 17, 2022 | EX3D | SOU EXTENSION 3 DENIAL LETTER PREPARED | — |
| May 17, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 17, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 11, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 10, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 9, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 9, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 9, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 9, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 5, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 5, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 5, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 11, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 16, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 16, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 24, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 9, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 9, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 9, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 9, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 9, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 5, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 9, 2020 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Dec 8, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 23, 2020 | NWAP | NEW APPLICATION ENTERED | — |